Publication

Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. 2013. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol. 71:1567–76. doi:10.1007/s00280-013-2156-3.

Berglund E, Berglund D, Akcakaya P, Ghaderi M, Daré E, Berggren P-O, Köhler M, Aspinwall CA, Lui W-O, Zedenius J, et al. 2013. Evidence for Ca(2+)-regulated ATP release in gastrointestinal stromal tumors. Exp Cell Res. 319:1229–38. doi:10.1016/j.yexcr.2013.03.001.

Lencinas A, Chhun DC, Dan KP, Ross KD, Hoover EA, Antin PB, Runyan RB. 2013. Olfactomedin-1 activity identifies a cell invasion checkpoint during epithelial-mesenchymal transition in the chick embryonic heart. Dis Model Mech. 6:632–42. doi:10.1242/dmm.010595.

Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihs K, López AM. 2013. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology. 22:1035–42. doi:10.1002/pon.3101.

Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL. 2013. Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod. 76:316–21. doi:10.1021/np300663v.

Cance WG, Kurenova E, Marlowe T, Golubovskaya V. 2013. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal. 6:pe10. doi:10.1126/scisignal.2004021.

Bernstein C, Nfonsam V, Prasad AR, Bernstein H. 2013. Epigenetic field defects in progression to cancer. World J Gastrointest Oncol. 5:43–9. doi:10.4251/wjgo.v5.i3.43.

Fritz BG, Roberts SA, Ahmed A, Breci L, Li W, Weichsel A, Brailey JL, Wysocki VH, Tama F, Montfort WR. 2013. Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking. Biochemistry. 52:1568–82. doi:10.1021/bi301570m.

Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et al. 2013. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(7):895–902. doi:10.1200/jco.2011.40.1174.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, et al. 2013. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 73:328–35. doi:10.1002/pros.22573.

Bronnimann MP, Chapman JA, Park CK, Campos SK. 2013. A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection. J Virol. 87:464–73. doi:10.1128/JVI.01539-12.

Secomb TW, Alberding JP, Hsu R, Dewhirst MW, Pries AR. 2013. Angiogenesis: an adaptive dynamic biological patterning problem. PLoS Comput Biol. 9:e1002983. doi:10.1371/journal.pcbi.1002983.

Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. 2013. Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des. 19:6218–25. doi:10.2174/1381612811319340013.

Chen JL, Hsu A, Yang X, Li J, Lee Y, Parinandi G, Li H, Lussier YA. 2013. Curation-free biomodules mechanisms in prostate cancer predict recurrent disease. BMC Med Genomics. 6 Suppl 2:S4. doi:10.1186/1755-8794-6-S2-S4.

Agarwal A, Larsen BT, Buadu LD, Dunn J, Crawford R, Daniel J, Bishop MC. 2013. Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case Rep Oncol Med. 2013:496351. doi:10.1155/2013/496351.

Hruby VJ, Cai M. 2013. Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles. Annu Rev Pharmacol Toxicol. 53:557–80. doi:10.1146/annurev-pharmtox-010510-100456.

Bell ML, Kenward MG, Fairclough DL, Horton NJ. 2013. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ. 346:e8668. doi:10.1136/bmj.e8668.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, et al. 2013. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res. 28:92–107. doi:10.1002/jbmr.1732.

Phipps-Yonas H, Cui H, Sebastiao N, Brunhoeber PS, Haddock E, Deymier MJ, Klapper W, Lybarger L, Roe DJ, Hastings KT. 2013. Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma. Front Immunol. 4:425. doi:10.3389/fimmu.2013.00425.

Harper JN, Wright SH. 2013. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol. 304:F56–67. doi:10.1152/ajprenal.00486.2012.

Schoenberg NE, Studts CR, Hatcher-Keller J, Buelt E, Adams E. 2013. Patterns and determinants of breast and cervical cancer non-screening among Appalachian women. Women Health. 53:552–71. doi:10.1080/03630242.2013.809400.

Montilla LG, Olafsson R, Bauer DR, Witte RS. 2013. Real-time photoacoustic and ultrasound imaging: a simple solution for clinical ultrasound systems with linear arrays. Phys Med Biol. 58:N1–12. doi:10.1088/0031-9155/58/1/N1.

Ruiz, J. M., Steffen, P., & Smith, T. B. (2013). The Hispanic mortality paradox: A systematic review and meta-analysis of the longitudinal literature. American Journal of Public Health, 103, e1-e9. 2013.

Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, Halpern MD. 2013. The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 304:G48–56. doi:10.1152/ajpgi.00317.2012.

Grigoriu S, Bond R, Cossio P, Chen JA, Ly N, Hummer G, Page R, Cyert MS, Peti W. 2013. The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol. 11:e1001492. doi:10.1371/journal.pbio.1001492.